Stock PHIL PHILOGEN S.P.A.
Add to a list
To use this feature you must be a member
Log inSign up

Philogen S.p.A. Stock

Equities

PHIL

IT0005373789

Biotechnology & Medical Research

Market Closed - Borsa Italiana
Other stock markets
 11:44:59 2024-06-14 am EDT 		5-day change 1st Jan Change
20.2 EUR +2.02% Intraday chart for Philogen S.p.A. -1.94% +9.19%
Jun. 06 Futures up slightly on ECB day AN
Jun. 05 Mib bullish ahead of ECB; STM and Nexi soar AN

Financials

Sales 2024 * 85.69M 91.71M Sales 2025 * 20.92M 22.39M Capitalization 814M 871M
Net income 2024 * 3M 3.21M Net income 2025 * -46M -49.23M EV / Sales 2024 * 8.68 x
Net cash position 2024 * 70.27M 75.2M Net cash position 2025 * 68.29M 73.09M EV / Sales 2025 * 35.6 x
P/E ratio 2024 *
224 x
P/E ratio 2025 *
-17.7 x
Employees 165
Yield 2024 *
-
Yield 2025 *
-
Free-Float 27%
More Fundamentals * Assessed data

Chart Philogen S.p.A.

Dynamic Chart

Latest news about Philogen S.p.A.

Futures up slightly on ECB day AN
Mib bullish ahead of ECB; STM and Nexi soar AN
Mib rises; ECB could push cyclical stocks up AN
Mib up at start, DiaSorin good on FDA news AN
Indices expected to rise before PMIs AN
Mib bearish; Brunello Cucinelli the best AN
Mib falls in 34,100 area dragged by banks AN
Philogen, Inc. and Sun Pharmaceutical Industries Limited Announces Results of the Phase III PIVOTAL Trial of Nidlegy in Melanoma CI
Mib pegs 34,300; banking segment well AN
Mib veers upward; ERG takes top spot AN
Sales in Milan; but Philogen is at annual peak AN
Futures down; Brent advances to USD84 area AN
Mib in the red; BPER and Intesa resist declines AN
Mib down but Iveco and Pirelli soar AN
Philogen, NFP and liquidity drop in first quarter AN
More news

Latest transcript on Philogen S.p.A.

Logo Philogen S.p.A.
Philogen S.p.A., 2023 Earnings Call, Apr 03, 2024
More transcripts

Press releases Philogen S.p.A.

Philogen S p A : to attend the Chemical Biology conference at Novo Nordisk on June 8-9, 2024. PU
Philogen S p A : to attend the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 12, 2024. PU
Philogen S p A : is delighted to invite you to attend a virtual briefing on April 3, 2024 to discuss the Company’s Full Year 2023 Results. PU
Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma GL
Philogen S p A : to attend the Italian Mid Cap Conference organised by Mediobanca on January 23-24, 2024 PU
More press releases

News in other languages on Philogen S.p.A.

Futures in lieve rialzo nel giorno della BCCE
Mib rialzista prima della BCE; svettano STM e Nexi
Mib sale; BCE potrebbe spingere i titoli ciclici
Mib su in avvio, bene DiaSorin su news FDA
Indici attesi in rialzo prima dei PMI
More news

Quotes and Performance

1 day+2.02%
1 week-1.94%
Current month-4.72%
1 month+11.29%
3 months+15.43%
6 months+12.22%
Current year+9.19%
More quotes

Highs and lows

1 week
19.80
Extreme 19.8
20.80
1 month
17.60
Extreme 17.6
21.60
Current year
16.30
Extreme 16.3
21.60
1 year
14.90
Extreme 14.9
21.60
3 years
12.60
Extreme 12.6
21.60
5 years
12.60
Extreme 12.6
21.60
10 years
12.60
Extreme 12.6
21.60
More quotes

Managers and Directors - Philogen S.p.A.

Managers TitleAgeSince
Dario Neri CEO
 Chief Executive Officer 61 95-12-31
Duccio Neri FOU
 Founder 61 95-12-31
Laura Baldi DFI
 Director of Finance/CFO 52 -
Members of the board TitleAgeSince
Sergio Gianfranco Dompé BRD
 Director/Board Member 68 -
Leopoldo Giampaolo Zambeletti BRD
 Director/Board Member 55 -
Duccio Neri FOU
 Founder 61 95-12-31
More insiders

Quotes

Date Price Change Volume
24-06-14 20.2 +2.02% 2,642
24-06-13 19.8 -2.46% 4,837
24-06-12 20.3 -2.40% 3,703
24-06-11 20.8 0.00% 2,084
24-06-10 20.8 +0.97% 9,988

Real-time Borsa Italiana, June 14, 2024 at 11:44 am EDT

More quotes

Company Profile

Philogen SpA is an Italy-based company, operating in the biotechnology sector. The Company develops products and technologies for the diagnosis and therapy of serious human diseases. It has three anti-cancer antibody derivatives, produced with an in-house industrial process, into Phase I/II clinical studies. The majority of its technologies and products are based on high-affinity human monoclonal antibody fragments. Philogen SpA developed a patented technology, Iterative Colony Filter Screening, for the isolation of monoclonal antibodies, which requires neither immunization nor phage display. The Company's subsidiaries are Philotec, Philomed and Philochem. Philogen SpA is headquartered in Siena, Italy.
Sector
Biotechnology & Medical Research
Calendar
2024-09-24 - Q2 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Philogen S.p.A.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
20.2 EUR
Average target price
23.5 EUR
Spread / Average Target
+16.34%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
PHILOGEN S.P.A. Stock Philogen S.p.A.
+9.19% 871M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.15% 124B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+18.02% 112B
ARGENX SE Stock argenx SE
+5.07% 22.94B
BIONTECH SE Stock BioNTech SE
-12.75% 22.22B
BEIGENE, LTD. Stock BeiGene, Ltd.
-9.86% 17.02B
GENMAB A/S Stock Genmab A/S
-14.97% 16.88B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.94% 16.87B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.80% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.39% 11.61B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. PHIL Stock